Tin tức & Cập nhật
Xem bài viết Đa khoa
Xem
Chỉ hiển thị Multimedia
Subcutaneous on par with IV pembrolizumab for NSCLC
17 Jul 2025
bởiStephen Padilla
Pembrolizumab administered subcutaneously (SC) is noninferior to the intravenous (IV) strategy in terms of overall exposure and trough concentrations, with similar efficacy and consistent safety profiles in patients with treatment-naive metastatic nonsmall cell lung cancer (NSCLC), reports a study.
Subcutaneous on par with IV pembrolizumab for NSCLC
17 Jul 2025
Esketamine monotherapy shows robust, rapid efficacy as treatment for TRD
17 Jul 2025
bởiMike Ng
Intranasal esketamine, administered at two fixed doses as monotherapy for treatment-resistant depression (TRD), has demonstrated robust and rapid efficacy in a phase IV double-blind, placebo-controlled randomized trial.
